New therapeutic approaches are making advanced and metastatic prostate cancer more treatable through targeted drugs and nuclear-medicine-based therapies [1, 3].

These developments are critical because they provide options for patients who previously faced limited treatment paths, potentially extending survival and maintaining a higher quality of life for men with late-stage disease.

Medical experts at the Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, and Roswell Park Comprehensive Cancer Center in Buffalo, New York, said there is a shift toward multidisciplinary care [1, 2]. A key component of this progress is the rise of theranostics, a field that combines diagnostic imaging and targeted therapy to treat cancer cells with precision [1, 3].

Recent pharmacological advances include the introduction of capivasertib, marketed as Truqap [1, 3]. This targeted drug received FDA approval to treat specific forms of advanced prostate cancer that were previously difficult to manage [3]. Additionally, researchers are exploring BCL-2 inhibition as an emerging method to disrupt cancer cell survival [1, 2].

While advanced stages are becoming more manageable, early detection remains the most effective strategy. The five-year survival rate exceeds 99% when prostate cancer is detected in its early stages [4].

However, the benefit of these newer therapies is not universal. Some reports indicate that in certain regions, such as India, many men are diagnosed at a late stage, which can limit the effectiveness of these medical advances [5].

Despite these disparities, the integration of nuclear medicine and targeted agents continues to shift the prognosis for those with metastatic disease [1, 3].

“Advances in treatment are helping many patients live longer, stay active, and maintain a high quality of life.”

The shift toward precision medicine—specifically theranostics and targeted inhibitors—transforms advanced prostate cancer from a rapidly terminal diagnosis into a more manageable chronic condition for some patients. However, the gap between the availability of these high-tech treatments and global diagnostic rates suggests that medical innovation alone cannot solve the mortality rate without corresponding improvements in early screening access.